Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D08TXL
|
|||
| Former ID |
DNC008329
|
|||
| Drug Name |
A-796260
|
|||
| Synonyms |
895155-26-7; (1-(2-morpholinoethyl)-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone; A-796260; UNII-5N69DXA53Z; CHEMBL262865; 5N69DXA53Z; A 796260; A-796,260; ZCFHOMLAFTWDFM-UHFFFAOYSA-N; A796260; Morpholino-ethyl analogue, 32; SCHEMBL2076954; CTK8B4187; BDBM21311; MolPort-023-278-969; ZINC14975818; ANW-44204; AKOS015999103; (1-(2-morpholin-4-yl-ethyl)-1H-indol-3-yl)-(2,2,3,3-tetramethylcyclopropyl)methanone; KB-74376; AJ-65531; AS-19178; AX8228482; TC-132949; ST24020055; X5014; J3.566.431I
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Pain [ICD-11: MG30-MG3Z] | Investigative | [1] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C22H30N2O2
|
|||
| Canonical SMILES |
CC1(C(C1(C)C)C(=O)C2=CN(C3=CC=CC=C32)CCN4CCOCC4)C
|
|||
| InChI |
1S/C22H30N2O2/c1-21(2)20(22(21,3)4)19(25)17-15-24(18-8-6-5-7-16(17)18)10-9-23-11-13-26-14-12-23/h5-8,15,20H,9-14H2,1-4H3
|
|||
| InChIKey |
ZCFHOMLAFTWDFM-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 895155-26-7
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Cannabinoid receptor 1 (CB1) | Target Info | Inhibitor | [1] |
| Cannabinoid receptor 2 (CB2) | Target Info | Inhibitor | [1] | |
| KEGG Pathway | Rap1 signaling pathway | |||
| Neuroactive ligand-receptor interaction | ||||
| Retrograde endocannabinoid signaling | ||||
| Panther Pathway | Endogenous cannabinoid signaling | |||
| Pathway Interaction Database | N-cadherin signaling events | |||
| Reactome | Class A/1 (Rhodopsin-like receptors) | |||
| G alpha (i) signalling events | ||||
| WikiPathways | GPCRs, Class A Rhodopsin-like | |||
| Small Ligand GPCRs | ||||
| BDNF signaling pathway | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| GPCRs, Other | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Indol-3-ylcycloalkyl ketones: effects of N1 substituted indole side chain variations on CB(2) cannabinoid receptor activity. J Med Chem. 2010 Jan 14;53(1):295-315. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.